Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Adult patients ≥ 18 years and ≤ 75 years of age * Histologic or cytologic proven ductal adenocarcinoma of the pancreas (histologic confirmation of diagnosis is preferred) * No distant metastases * De novo, treatment-naïve unresectable or borderline resectable LAPC; evaluation of unresectable and borderline resectable status according to NCCN- Clinical Practice Guidelines in Oncology "pancreatic adenocarcinoma" version 1.2013. Applicable criterion/criteria have to be indicated. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Total bilirubin ≤ 2 mg/dL. Patients with a biliary stent may be included provided that bilirubin level after stent insertion decreased to ≤ 2 mg/dL and there is no cholangitis. * Adequate renal, hepatic and bone marrow function, defined as * Serum creatinine ≤ 1.25 x Upper limit of normal (ULN) * Calculated creatinine clearance ≥ 60 mL/min according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula * Aspartate aminotransferase (AST)/(serum glutamic oxaloacetic transaminase)GOT and/or Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (GPT) ≤ 2.5 x ULN * Partial thromboplastin time (PTT) ≤ 1.5 x ULN and Quick value ≥ 70% * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L * Haemoglobin ≥ 8g/dL * Platelets ≥ 100 x 109/L * Females of childbearing potential (FCBP) must have a negative pregnancy test within 7 days of the first application of study treatment and must agree to use ef…